Journal of Diagnostics Concepts & Practice ›› 2019, Vol. 18 ›› Issue (06): 640-644.doi: 10.16150/j.1671-2870.2019.06.007

• Original articles • Previous Articles     Next Articles

Diagnostic value of nerve electrophysiological studies for Bortezomib-induced peripheral neuropathy in multiple myeloma patients

LU Hongyu1, CAO Yafeng1, GU Jun1, WANG Jing1, CHEN Mei1(), SONG Luxi2()   

  1. 1. Department of Hematology, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, China
    2. Department of Hematology, Shanghai No.6 people’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China
  • Received:2019-05-08 Online:2019-12-25 Published:2019-12-25
  • Contact: CHEN Mei,SONG Luxi E-mail:cm6825@126.com;songluxi@189.cn

Abstract:

Objective: To study the diagnostic value of nerve electrophysiological studies (NES) for Bortezomib-induced peripheral neuropathy (BiPN) in patients with multiple myeloma(MM). Methods: A total of 79 patients with MM treated with bortezomib based induction chemotherapy were enrolled. The baseline and post-treatment perpheral neuropathy(PN) was assessed by clinical adverse effects and NES, and the results between these two assessing methods were compared. Results: Thirty-one of 79 (39.2%) MM patients had baseline NES abnormalities before treated with bortezomib, of them 20 (64.5%) patients developed BiPN at last, and early and grade 2 or higher BiPN also concentrated in patients with abnormal baseline NES. Compared with bone marrow plasma cells, serum LDH, β2 microglobulin and other prognostic related clinical and laboratory indices, abnormal baseline NES was the only index that had significant difference between groups having or not having BiPN ( χ2=6.410, P=0.011). After 4 courses of treatment, 33 patients were diagnosed as having BiPN, among them 25(75.8%) patients were diagnosed by clinical adverse effects and 17 (51.5%) patients by subsequent NES. There was no significant difference in positive rate between the two assessment methods ( χ2=3.803, P=0.051). Of the 33 patients diagnosed as having BiPN, the diagnostic results of clinical adverse effects and of subsequent NES were consistent in 9 patients (27.3%) and inconsistent in 24 cases (72.7%), the consistency between the two assessment methods was poor (rn=0.220, P=0.051). Conclusions: Abnormal baseline NES has some value for the prediction of BiPN, however, clinical assessment is still important for BiPN, and subsequent NES can be served as a supplement for clinical assessment of BiPN.

Key words: Multiple myeloma, Peripheral neuropathy, Bortezomib, Nerve electrophysiology

CLC Number: